momelotinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Myelofibrosis

Pending FDA approval for treating and reducing key hallmarks of myelofibrosis (eg, anemia, splenomegaly)

Next:

Pharmacology

Mechanism of Action

Inhibits signals along 3 pathways – Janus kinase (JAK) 1, JAK2, and activin A receptor type 1 (ACVR1)

Competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and therefore, induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells

JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorder

ACVR1 is a protein which in humans is encoded by the ACVR1 gene; also known as ALK-2 (activin receptor-like kinase-2); transduces signals of bone morphogenetic protein (BMP)

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.